IMMUPHARMA PLC — Regulatory Filings 2018

Mar 23, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6822I

Immupharma PLC

23 March 2018

23 March 2018

ImmuPharma PLC

("ImmuPharma" or the "Company")

Lupuzor™ Pivotal Phase III Study Update

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company announces  that it has been informed by Simbec-Orion, the contract research organisation conducting our Lupuzor™ pivotal Phase III trial study, that 'database lock' is expected on 6 April 2018, with top line results announced by mid-April 2018.

Lupuzor™ is the Company's lead programme for the potential breakthrough compound for Lupus, a life threatening autoimmune disease.

Commenting on the trial update, Tim McCarthy, Chairman, said: "With the continued robust safety record of Lupuzor™ achieved over this trial, we look forward with confidence to reporting top line results in the near future."

For more information on the trial please visit: https://clinicaltrials.gov/ct2/show/NCT02504645

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

For further information please contact:

ImmuPharma plc (www.immupharma.com)	+ 44 (0) 20 7152 4080
Tim McCarthy, Chairman
Lisa Baderoon, Head of Investor Relations Twitter: @immupharma	+ 44 (0) 7721 413496
Northland Capital Partners Limited David Hignell, Dugald Carlean, Jamie Spotswood, Corporate Finance Rob Rees, Corporate Broking	+44 (0)20 3861 6625

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCFKBDDCBKDNNB